Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Beers

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral SclerosisJason R Thonhoff, James D Berry, Eric A Macklin, et al.
Translational Neurodegeneration|November 16, 2023
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's diseaseAlireza Faridar, Abdulmunaim M Eid, Aaron D Thome, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 9, 2018
An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosisChristina N Fournier, David Schoenfeld, James D Berry, et al.
JAMA Neurology|April 25, 2017
Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis MonocytesWeihua Zhao, David R Beers, Kristopher G Hooten, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 30, 2025
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastasesPaolo Zanotti-Fregonara, Monika Vishnoi, Quentin Finn, et al.
Acta Neuropathologica Communications|September 30, 2022
Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's diseaseAlireza Faridar, Matthew Vasquez, Aaron D Thome, et al.
Alzheimer'S Research & Therapy|July 4, 2025
Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trialAlireza Faridar, Nazaret Gamez, Daling Li, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral SclerosisJason R Thonhoff, James D Berry, Eric A Macklin, et al.
Translational Neurodegeneration|November 16, 2023
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's diseaseAlireza Faridar, Abdulmunaim M Eid, Aaron D Thome, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 9, 2018
An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosisChristina N Fournier, David Schoenfeld, James D Berry, et al.
JAMA Neurology|April 25, 2017
Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis MonocytesWeihua Zhao, David R Beers, Kristopher G Hooten, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 30, 2025
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastasesPaolo Zanotti-Fregonara, Monika Vishnoi, Quentin Finn, et al.
Acta Neuropathologica Communications|September 30, 2022
Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's diseaseAlireza Faridar, Matthew Vasquez, Aaron D Thome, et al.
Alzheimer'S Research & Therapy|July 4, 2025
Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trialAlireza Faridar, Nazaret Gamez, Daling Li, et al.
Pageof 5